We value your privacy

This website or its third-party tools process personal data. You can opt out of the sale of your personal information by clicking on the “Do Not Sell or Share My Personal Information” link.

Powered by

Emgality

ACNU Feasibility

View full report
ExcellentEmgality is generally safe with mild side effects, low misuse risk, and minimal drug interactions. It requires subcutaneous injection, occasional monitoring, and caution in special populations, with monthly dosing aiding adherence but posing minor usability challenges.

ACNU Feasibility Scorecard

Chart with 11 data points.
Emgality
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 1 to 5.
End of interactive chart.